BioMedNewsBreaks

TuesdayMar 26, 2024 3:47 pm

BioMedNewsBreaks – NextPlat Corp. (NASDAQ: NXPL) Expands Technology E-Commerce Portfolio Through Strategic Acquisition

NextPlat (NASDAQ:NXPL, NXPLW), a global e-commerce provider, today announced the significant expansion of its North American e-commerce business with the acquisition of Outfitter Satellite Inc. through an all-cash transaction. According to the announcement, the transaction is expected to close on April 1, 2024. “Outfitter is an ideal addition to our technology e-commerce portfolio, delivering immediate synergies and value, quickly and profitably adding scale to our North American operations,” said Charles M. Fernandez, executive chairman and CEO of NextPlat. “Through acquisitions such as Outfitter and the introduction of new technology and healthcare e-commerce offerings expected later this year, we are executing…

Continue Reading

MondayMar 25, 2024 3:24 pm

BioMedNewsBreaks – Lumos Pharma Inc. (NASDAQ: LUMO) Receives Patent Notice for Improved Formulation of Lead Therapeutic Candidate

Lumos Pharma (NASDAQ: LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for pediatric growth hormone deficiency (“PGHD”) through phase 2 clinical trials, has received a notice of allowance for a submitted patent. The notice was received from the U.S. Patent and Trade Office (“USPTO”) earlier this month; the notice covers claims the company made for its patent titled “Compactable Oral Formulations of Ibutamoren.” According to the announcement, the patent includes improved formulations of LUM-201 that the company plans to use in its phase 3 trial and eventually commercialize. LUM-201 (ibutamoren) is an orally administered small molecule that promotes the secretion…

Continue Reading

MondayMar 25, 2024 3:00 pm

BioMedNewsBreaks – Astrotech Corporation (NASDAQ: ASTC) Launches ‘Gold Standard’ of Mass Spectrometry into Narcotics Detection Market

Astrotech (NASDAQ: ASTC) and its wholly owned subsidiary, 1st Detect Corporation, today announced that the company is currently accepting orders for the Tracer 1000 Narcotics Trace Detector (“NTD”). A high-performance laboratory instrument, the TRACER 1000 NTD is capable of rapid detection of trace levels of narcotic compounds in seconds. With the company’s Tracer 1000 Explosive Trace Detector (“ETD”) now found in multiple locations in 14 countries, the NTD provides a ruggedized platform that can be applied across various markets including airports, border security, checkpoint, cargo, and infrastructure security, correctional facilities, military, and law enforcement. “Over the last five years our…

Continue Reading

MondayMar 25, 2024 11:31 am

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Closes on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has closed on its registered direct offering. The offering, which was priced in accordance with NASDAQ guidelines, iincluded the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) and warrants to purchase up to 1,542,112 shares of common stock. Pricing was $4.215 per share of common stock (or prefunded warrant) and accompanying warrant, resulting in approximately $6.5 million before deducting typical fees and offering expenses. According to the announcement, the warrants have an exercise price of $4.09 per share and…

Continue Reading

ThursdayMar 21, 2024 3:35 pm

BioMedNewsBreaks — Astiva Health Is Reshaping Healthcare Delivery

Astiva Health CEO Dr. Tri Nguyen was the featured guest in a recent Bell2Bell Podcast episode. “During the podcast, Nguyen provided an in-depth look at how Astiva Health is reshaping healthcare delivery, including an overview of the company’s commitment to patient involvement in healthcare and highlights of the company’s innovative strategies in offering comprehensive care… ‘So Astiva, other than providing full medical-care prescription drugs, we also focus on providing very rich supplemental benefits to our enrollees and getting them involved, participating and aiming for an active, healthy and meaningful life,’” reads a recent article, which contains quotes from the discussion.…

Continue Reading

ThursdayMar 21, 2024 12:34 pm

BioMedNewsBreaks — HeartBeam Inc. (NASDAQ: BEAT) Releases Financial Results, Corporate Highlights for Q4, FY 2023

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, has announced its financial numbers and operational highlights for the fourth quarter and full year ended Dec. 31, 2023. According to the report, key achievements during the period included enrolling the first patients for a pivotal trial studying AIMIGo(TM) System for synthesizing a 12-lead ECG as well as clinical and regulatory progress made for the AIMIGo 3D VECG system. In addition, the company noted it had received two new patents during the period, covering HeartBeam’s proprietary technologies. “We have continued to make…

Continue Reading

WednesdayMar 20, 2024 1:50 pm

BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focusing on the development of novel anti-purinergic therapies (“APTs”), is focusing its lead program on autism spectrum disorder (“ASD”), for which there is no approved pharmacologic treatment targeting cause and symptoms. “The current ASD treatments only address the symptoms of the condition but do not target the pathophysiology itself. PaxMedica is on a promising path to address the unmet medical needs of families with ASD – bringing hope to millions,” a recent article reads. “PaxMedica is using existing research on a drug called suramin, initially created to treat a disease called Human African…

Continue Reading

WednesdayMar 20, 2024 12:57 pm

BioMedNewsBreaks – Genprex Inc. (NASDAQ: GNPX) Releases Info on $6.5M Registered Direct Offering

Genprex (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, has entered into definitive agreements. The agreements are for the sale and issuance of 1,542,112 shares of common stock (or prefunded warrants in lieu thereof) of the company and warrants to purchase up to 1,542,112 shares of common stock; the stocks and warrants are offered at a combined price of $4.215 per share of common stock (or per prefunded warrant in lieu thereof) and accompanying warrant. Genprex will be receive approximately $6.5 million in gross proceeds from the offering, before standard fees and…

Continue Reading

WednesdayMar 20, 2024 12:41 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Developing Innovative Technologies to Address Critical Healthcare Challenges

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, recently expanded its therapeutic candidates, introducing ImmunePrep(TM) to improve the delivery of immunotherapeutic antibodies to treat cancer. “The company is also developing ChemoPrep(TM) and ChemoPure(TM) to optimize chemotherapy delivery and reduce treatment toxicity. The company further disclosed that clinical site locations for first-in-human studies for Sigyn Therapy(TM) have been identified. Sigyn Therapy(TM) is a novel blood purification technology to treat pathogen-associated conditions that are beyond the reach of drugs,” a recent article reads. “Sigyn Therapeutics is developing innovative medical technologies to address critical healthcare challenges. The company’s technologies show promise in…

Continue Reading

WednesdayMar 20, 2024 12:29 pm

BioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) Board Approves 1-for-10 Reverse Stock Split

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines for unmet medical needs, has announced a 1-for-10 reverse split of the company’s Class A common stock. The move was approved by the company’s board of directors during a special stockholder meeting. According to the announcement, the reverse split will become effective at 11:59 p.m. ET on March 26, 2024. Following that, the company’s Class A common stock will begin trading on the NASDAQ Capital Market on a split-adjusted basis. “The reverse split is intended to increase the per share trading price of the company’s common stock to enable the…

Continue Reading